Comparison 11. H2 receptor antagonists versus sucralfate.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinically important upper GI bleeding	24	3316	Risk Ratio (M‐H, Fixed, 95% CI)	1.10 [0.87, 1.41]
1.1 Cimetidine vs sucralfate	7	873	Risk Ratio (M‐H, Fixed, 95% CI)	1.37 [0.87, 2.14]
1.2 Famotidine vs sucralfate	2	190	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.21, 1.78]
1.3 Ranitidine vs sucralfate	14	2186	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.76, 1.39]
1.4 Cimetidine + pirenzepine vs sucralfate + pirenzepine	1	67	Risk Ratio (M‐H, Fixed, 95% CI)	5.15 [0.26, 103.33]
2 Nosocomial pneumonia	17	3041	Risk Ratio (M‐H, Fixed, 95% CI)	1.22 [1.07, 1.40]
2.1 Cimetidine vs sucralfate	5	758	Risk Ratio (M‐H, Fixed, 95% CI)	1.13 [0.87, 1.47]
2.2 Famotidine vs sucralfate	1	140	Risk Ratio (M‐H, Fixed, 95% CI)	1.13 [0.40, 3.20]
2.3 Ranitidine vs sucralfate	11	2143	Risk Ratio (M‐H, Fixed, 95% CI)	1.26 [1.07, 1.48]
3 All‐cause mortality in ICU	21	3178	Risk Ratio (M‐H, Fixed, 95% CI)	1.09 [0.95, 1.24]
3.1 Cimetidine vs sucralfate	6	814	Risk Ratio (M‐H, Fixed, 95% CI)	1.18 [0.91, 1.54]
3.2 Famotidine vs sucralfate	2	190	Risk Ratio (M‐H, Fixed, 95% CI)	1.23 [0.69, 2.19]
3.3 Ranitidine vs sucralfate	12	2107	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.88, 1.22]
3.4 Cimetidine + pirenzepine vs sucralfate + pirenzepine	1	67	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.38, 4.38]
4 All‐cause mortality in hospital	4	717	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [0.86, 1.50]
4.1 Cimetidine vs sucralfate	2	413	Risk Ratio (M‐H, Fixed, 95% CI)	1.28 [0.86, 1.92]
4.2 Ranitidine vs sucralfate	1	164	Risk Ratio (M‐H, Fixed, 95% CI)	1.11 [0.71, 1.74]
4.3 Famotidine vs sucralfate	1	140	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.40, 1.71]
5 Duration of intubation	10	1751	Mean Difference (IV, Random, 95% CI)	0.22 [‐1.55, 2.00]
5.1 Cimetidine vs sucralfate	2	97	Mean Difference (IV, Random, 95% CI)	0.58 [‐1.71, 2.87]
5.2 Famotidine vs sucralfate	1	140	Mean Difference (IV, Random, 95% CI)	0.40 [‐2.30, 3.10]
5.3 Ranitidine vs sucralfate	7	1514	Mean Difference (IV, Random, 95% CI)	0.15 [‐2.12, 2.43]
6 Duration of ICU stay	6	1791	Mean Difference (IV, Random, 95% CI)	0.01 [‐1.92, 1.95]
6.1 Cimetidine vs sucralfate	1	213	Mean Difference (IV, Random, 95% CI)	0.0 [‐3.05, 3.05]
6.2 Famotidine vs sucralfate	1	140	Mean Difference (IV, Random, 95% CI)	2.20 [‐0.96, 5.36]
6.3 Ranitidine vs sucralfate	4	1438	Mean Difference (IV, Random, 95% CI)	‐0.43 [‐2.70, 1.84]
7 Number of participants requiring blood transfusion	9	1095	Risk Ratio (M‐H, Fixed, 95% CI)	1.25 [0.70, 2.23]
7.1 Cimetidine vs sucralfate	5	732	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.47, 2.16]
7.2 Ranitidine vs sucralfate	4	363	Risk Ratio (M‐H, Fixed, 95% CI)	1.77 [0.71, 4.39]
8 Units of blood transfused	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
8.1 Cimetidine vs sucralfate	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
9 Adverse events of interventions	6		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
9.1 Thrombocytopaenia	2	240	Risk Ratio (M‐H, Fixed, 95% CI)	4.72 [0.56, 39.47]
9.2 Nausea and vomiting	2	137	Risk Ratio (M‐H, Fixed, 95% CI)	0.07 [0.01, 0.54]
9.3 Hypermagnesaemia	1	40	Risk Ratio (M‐H, Fixed, 95% CI)	2.71 [0.31, 23.93]
9.4 Rash/Erythema	2	233	Risk Ratio (M‐H, Fixed, 95% CI)	3.06 [0.32, 28.87]
9.5 Confusion	3	382	Risk Ratio (M‐H, Fixed, 95% CI)	4.48 [0.77, 26.00]
9.6 Neutropaenia	1	114	Risk Ratio (M‐H, Fixed, 95% CI)	5.18 [0.25, 105.47]
9.7 Dryness of mouth	1	67	Risk Ratio (M‐H, Fixed, 95% CI)	5.15 [0.26, 103.33]
9.8 Leucopaenia	1	163	Risk Ratio (M‐H, Fixed, 95% CI)	3.11 [0.13, 75.26]